As the signs point toward a potential Evotec acquisition, delve into what it could represent for the European biotech ...

Halozyme made the €11-per-share offer earlier this month, valuing Evotec at around €2 billion ($2.1 billion), saying at the ...

Evotec's COO Craig Johnstone will leave by year-end as the company implements its Priority Reset restructuring amid declining ...

Evotec (EVO) announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the company effective December 31. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery ...

EQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution ...

Highlights:,Dr. Craig Johnstone to step down as COO effective December 31, 2024, after a 12-year tenure at Evotec.,Johnstone ...

HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig ...

Evotec said Friday that its Chief Operating Officer Craig Johnstone will step down and leave the company in December. The German drug developer said Johnstone's responsibilities will be distributed ...

Analysis of Halozyme Therapeutics, Inc.'s recent developments including revenue growth, patent expiration concerns, and new ...

This table compares Evotec and Sagimet Biosciences’ net margins, return on equity and return on assets. 5.8% of Evotec shares are owned by institutional investors. Comparatively, 87.9% of ...

The company's recent appearance at the Frankfurt Equity Forum left many strategic questions unanswered, highlighting the significant challenges Evotec faces in its future strategic positioning. Fresh ...